Published in J Invest Dermatol on February 01, 2007
Th17 cells in human disease. Immunol Rev (2008) 4.27
The functional network of ion channels in T lymphocytes. Immunol Rev (2009) 3.21
Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov (2009) 3.12
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev (2008) 1.52
Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol (2009) 1.29
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther (2012) 1.19
Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets (2011) 1.15
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol (2009) 1.08
Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) (2007) 1.06
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol (2010) 1.03
Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc (2009) 1.02
Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol (2012) 0.98
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res (2011) 0.98
Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol (2010) 0.89
Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells. PLoS One (2013) 0.86
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J (2014) 0.84
Ion channels and anti-cancer immunity. Philos Trans R Soc Lond B Biol Sci (2014) 0.82
The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker. PLoS One (2012) 0.82
Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions. Nat Commun (2017) 0.82
Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis (2014) 0.81
Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers. PLoS One (2012) 0.81
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem (2008) 0.81
Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol (2009) 0.81
Role of the K(Ca)3.1 K+ channel in auricular lymph node CD4+ T-lymphocyte function of the delayed-type hypersensitivity model. Br J Pharmacol (2013) 0.81
Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem (2010) 0.80
The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLoS One (2013) 0.79
Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. J Autoimmun (2014) 0.79
Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia (2016) 0.76
Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica (2010) 0.76
Effect of the Kv1.3 voltage-gated potassium channel blocker PAP-1 on the initiation and progress of atherosclerosis in a rat model. Heart Vessels (2014) 0.76
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opin Ther Pat (2010) 0.76
Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev (2016) 0.75
Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury. Exp Neurol (2016) 0.75
Factors influencing adverse skin responses in rats receiving repeated subcutaneous injections and potential impact on neurobehavior. Curr Neurobiol (2014) 0.75
Mechanism of functional interaction between potassium channel Kv1.3 and sodium channel NavBeta1 subunit. Sci Rep (2017) 0.75
Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant. Proc Natl Acad Sci U S A (2016) 0.75
Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorg Med Chem Lett (2012) 0.75
T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers. PLoS One (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature (1997) 9.99
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity (2002) 9.29
Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature (1993) 8.20
Human IL-17: a novel cytokine derived from T cells. J Immunol (1995) 6.65
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature (1984) 4.70
Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol (2006) 3.78
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today (1998) 3.12
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol (2001) 3.00
Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem (2000) 2.85
Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol (2005) 2.83
Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A (2001) 2.63
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol (2002) 2.41
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05
A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J Biol Chem (1997) 2.05
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med (2000) 2.00
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest (2002) 1.95
Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol (2001) 1.85
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
CD4+ T-cell memory, CD45R subsets and the persistence of antigen--a unifying concept. Immunol Today (1998) 1.80
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest (2001) 1.74
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A (2000) 1.53
Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J Exp Med (2000) 1.52
Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel (2003) 1.52
Allergic contact dermatitis. Eur J Dermatol (2004) 1.52
Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine (1999) 1.45
New insights into endotoxin-induced activation of macrophages: involvement of a K+ channel in transmembrane signaling. J Immunol (2001) 1.36
Complex subunit assembly of neuronal voltage-gated K+ channels. Basis for high-affinity toxin interactions and pharmacology. J Biol Chem (1997) 1.35
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol (2002) 1.33
Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist (2005) 1.32
Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J Biol Chem (2003) 1.31
Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol (2004) 1.24
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22
Pimecrolimus: a review. J Eur Acad Dermatol Venereol (2003) 1.21
Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol (1999) 1.19
Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2003) 1.12
Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther (2002) 1.09
Role of cytokines in epidermal Langerhans cell migration. J Leukoc Biol (1999) 1.07
Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation. J Exp Med (2002) 1.07
CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol (2004) 1.03
Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation. Inflammation (1993) 1.02
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol (2002) 1.02
Voltage-activated proton currents in human THP-1 monocytes. J Membr Biol (1996) 0.98
CD8+ T cells are effector cells of contact dermatitis to common skin allergens in mice. J Invest Dermatol (2006) 0.96
Contact dermatitis I. Pathophysiology of contact sensitivity. Eur J Dermatol (1999) 0.92
Sensitization versus elicitation in allergic contact dermatitis: potential differences at cellular and molecular levels. Am J Contact Dermat (2000) 0.90
A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol (1997) 0.90
The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol Appl Pharmacol (2005) 0.89
Identification of Kv1.1 expression by murine CD4-CD8- thymocytes. A role for voltage-dependent K+ channels in murine thymocyte development. J Biol Chem (1995) 0.89
Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88
Evaluation of the skin sensitization potential of chemicals using expression of co-stimulatory molecules, CD54 and CD86, on the naive THP-1 cell line. Toxicol In Vitro (2003) 0.87
Chemical allergy: considerations for the practical application of cytokine profiling. Toxicol Sci (2003) 0.82
Enhancement of the contact hypersensitivity reaction by acute morphine administration at the elicitation phase. Clin Immunol (1999) 0.80
Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen. Toxicol Appl Pharmacol (2005) 0.80
Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol (2003) 0.80
Dissociation between sex differences in the immunological, behavioral, and physiological effects of kappa- and delta-opioids in Fischer rats. Psychopharmacology (Berl) (2006) 0.79
Development of a non-radioactive endpoint in a modified local lymph node assay. Food Chem Toxicol (1999) 0.78
Local lymph node assay with non-radioisotope alternative endpoints. J Toxicol Sci (2002) 0.76
Qualitative and quantitative evaluation of a local lymph node assay based on ex vivo interleukin-2 production. Toxicology (2005) 0.76
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev (2005) 2.39
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation (2009) 1.86
Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem (2007) 1.85
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int (2008) 1.80
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol (2008) 1.58
Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci (2011) 1.46
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A (2009) 1.44
Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proc Natl Acad Sci U S A (2008) 1.38
Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem (2010) 1.37
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol (2004) 1.31
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A (2010) 1.29
Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets (2010) 1.29
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem (2003) 1.22
Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol (2005) 1.17
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J (2005) 1.11
Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl) (2012) 1.09
The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab (2011) 1.08
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol (2009) 1.08
Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol (2012) 1.05
The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell (2009) 1.03
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet (2002) 1.01
Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. Technol Cancer Res Treat (2002) 0.99
The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochem J (2004) 0.98
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res (2011) 0.98
L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res (2012) 0.98
AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology (2007) 0.94
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem (2001) 0.94
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One (2012) 0.94
The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem (2013) 0.93
Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem (2004) 0.93
Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Mol Pharmacol (2011) 0.92
Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr Med Chem (2004) 0.92
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem (2014) 0.89
Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol (2010) 0.89
Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One (2013) 0.89
Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. Int J Alzheimers Dis (2012) 0.89
Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol (2012) 0.88
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem (2006) 0.88
A phase II trial of image-guided radiofrequency ablation of small invasive breast carcinomas: use of saline-cooled tip electrode. Ann Surg Oncol (2007) 0.86
Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respir Res (2014) 0.86
Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol Pharmacol (2005) 0.86
Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new κ-KTX subfamily. Biochem Pharmacol (2012) 0.86
Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. Br J Pharmacol (2013) 0.85
SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts. Cardiovasc Res (2012) 0.85
Does microglial dysfunction play a role in autism and Rett syndrome? Neuron Glia Biol (2012) 0.84
Molecular characterization of isosporoid coccidia (Isospora and Atoxoplasma spp.) in passerine birds. J Parasitol (2005) 0.84
K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLoS One (2013) 0.84
Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3. PLoS One (2013) 0.84
Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Mol Pharmacol (2014) 0.82
Shc depletion stimulates brown fat activity in vivo and in vitro. Aging Cell (2014) 0.82
The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets (2013) 0.82
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem (2008) 0.81
Kinetics of transmission, infectivity, and genome stability of two novel mouse norovirus isolates in breeding mice. Comp Med (2009) 0.81
Ultrasound detection and characterization of polycystic kidney disease in a mouse model. Comp Med (2006) 0.81
Haemoproteus spp. and Leukocytozoon spp. in a captive raptor population. J Wildl Dis (2004) 0.80
The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLoS One (2013) 0.79
The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics (2015) 0.79
Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Drug Dev Ind Pharm (2010) 0.78
The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation (2013) 0.78
Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay Drug Dev Technol (2013) 0.77
Channels: Sticking to nooks and crannies. Nat Chem Biol (2013) 0.77
Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure. Pflugers Arch (2014) 0.77
Triarylmethanes, a new class of cx50 inhibitors. Front Pharmacol (2012) 0.76
Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. Pflugers Arch (2014) 0.76
Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorg Med Chem Lett (2012) 0.75
Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels. J Cardiovasc Pharmacol (2015) 0.75
A simple device to illustrate the Einthoven triangle. Adv Physiol Educ (2012) 0.75
Development of tetramethylenedisulfotetramine (TETS) hapten library: synthesis, electrophysiological studies and immune response in rabbits. Chemistry (2017) 0.75
Ion channels. Thorax (2013) 0.75
Estradiol administration to ovariectomized rats potentiates mephedrone-induced disruptions of nonspatial learning. J Exp Anal Behav (2014) 0.75